Healthcare Sep 03, 2021 09:18 AM (GMT+8) · EqualOcean
3 days ago, the European bio health company (600867.SH) was informed that recently, the synthetic biology enterprise, kolai Biotechnology (Shanghai) Limited by Share Ltd (hereinafter referred to as "ikolai biology") has released the latest news. It has been officially approved by the National Drug Regulatory Commission's drug review center (CDE) with the joint application of the gitlitine generic drug joint application with the leading diabetic enterprise in China. This marks that the first product produced based on biosynthesis technology of Ecole biology in the pharmaceutical field has been approved for listing. Relying on the cell-free biosynthesis technology with independent intellectual property rights, it breaks the innovative application boundary of synthetic biology technology in the domestic pharmaceutical field. It is understood that the drug is the first drug variety using non hydrolase biosynthesis approved by CDE in recent years. It is also the first drug variety approved based on biosynthesis after the four departments jointly issued the guidance on promoting green development of API industry to encourage green technology manufacturing in early 2020.